HIGHLIGHTS
- who: BRAF in-frame deletion mutation and colleagues from the University of Texas MD Anderson Cancer Center, United States have published the article: BRAF L485 - P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review, in the Journal: (JOURNAL)
- what: Study, the authors report a class II BRAF rare mutant metastatic melanoma patient who has benefited from the BRAFi and MEKi combination therapy.
- future: By Frontiers in Pharmacology frontiersin.org 10.3389/fphar.2022.1019217 landscape of BRAF deletion mutant melanoma and further investigation by clinical . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.